Combined hepatocellular carcinoma and cholangiocarcinoma
MONDO:0044791A rare tumor containing unequivocal elements of both hepatocellular and cholangiocarcinoma that are intimately admixed. This tumor should be distinguished from separate hepatocellular carcinoma and cholangiocarcinoma arising in the same liver. The prognosis of this tumor is poor.
Also known as: carcinoma of liver and intrahepatic biliary tract, liver and intrahepatic biliary tract carcinoma, Cholangiohepatoma, Hepatocholangiocarcinoma, Mixed hepatocellular cholangiocarcinoma, carcinoma of the liver and intrahepatic biliary tract, combined hepatocellular cancer and cholangiocarcinoma (bile duct cancer), combined hepatocellular cancer and intrahepatic bile duct cancer (cholangiocarcinoma)
2972 clinical trials for this condition and its sub-types, 8 tagged with Combined hepatocellular carcinoma and cholangiocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Triple-Drug attack shows promise against tough liver cancer
Disease control OngoingThis study tests whether adding two targeted drugs (atezolizumab and bevacizumab) to standard chemotherapy helps people with a rare, advanced liver cancer live longer without their disease getting worse. About 88 adults with cancer that cannot be surgically removed will be random…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug combo shows promise against tough bile duct cancer
Disease control OngoingThis phase 2 trial tests whether adding pevonedistat to standard chemotherapy (carboplatin and paclitaxel) can shrink tumors in people with advanced bile duct cancer that has spread or cannot be removed. About 40 adults whose cancer progressed after gemcitabine-based chemo will r…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Cold climate liver cancer study tests new drug combos
Disease control OngoingThis study looks at how well immunotherapy drug combinations work for people with liver cancer living in cold parts of China. Researchers will track 1,000 patients to see if these treatments help them live longer and slow cancer growth. The goal is to find the best treatment plan…
Sponsor: Harbin Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC